{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:08:54Z","timestamp":1774026534819,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12891-015-0805-x","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T12:13:03Z","timestamp":1447243983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment"],"prefix":"10.1186","volume":"16","author":[{"given":"Gary J.","family":"Macfarlane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxwell S.","family":"Barnish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Keat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen T.","family":"Meldrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ejaz","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger D.","family":"Sturrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Zabke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"McNamee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,11]]},"reference":[{"key":"805_CR1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/art.24483","volume":"60","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Haibel H, Baraliakos X, Listing J, M\u00e4rker\u2010Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: Results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60:717\u201327.","journal-title":"Arthritis Rheum."},{"key":"805_CR2","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1136\/ard.61.suppl_3.iii8","volume":"61","author":"J Sieper","year":"2002","unstructured":"Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: An overview. Ann Rheum Dis. 2002;61:iii8\u2013iii18.","journal-title":"Ann Rheum Dis"},{"key":"805_CR3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10067-005-1150-5","volume":"25","author":"A \u00d6zg\u00fcl","year":"2006","unstructured":"\u00d6zg\u00fcl A, Peker F, Taskaynatan MA, Tan AK, Din\u00e7er K, Kalyon TA. Effect of ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients. Clin Rheumatol. 2006;25:168\u201374.","journal-title":"Clin Rheumatol."},{"key":"805_CR4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor \u03b1. N Engl J Med. 2002;346:1349\u201356.","journal-title":"N Engl J Med."},{"key":"805_CR5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semarthrit.2012.06.002","volume":"42","author":"S Brophy","year":"2013","unstructured":"Brophy S, Davies H, Dennis MS, Cooksey R, Husain MJ, Irvine E, et al. Fatigue in ankylosing spondylitis: Treatment should focus on pain management. Sem Arthritis Rheum. 2013;42:361\u20137.","journal-title":"Sem Arthritis Rheum."},{"key":"805_CR6","volume-title":"Adalimumab, etanercept and infliximab for ankylosing spondylitis","author":"National Institute for Health and Clinical Excellence","year":"2008","unstructured":"National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for ankylosing spondylitis. London: National Institute for Health and Clinical Excellence; 2008."},{"key":"805_CR7","unstructured":"National Institute for Health and Care Excellence. Final appraisal determination: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (including a review of TA143 and TA233). http:\/\/www.nice.org.uk\/guidance\/gid-tag355\/resources\/ankylosing-spondylitis-and-axial-spondyloarthritis-nonradiographic-adalimumab-etanercept-infliximab-and-golimumab-inc-rev-ta143-and-ta233-id694-final-appraisal-determination-document2 (2015). Accessed 8 October 2015."},{"key":"805_CR8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3310\/hta9380","volume":"9","author":"C Bartlett","year":"2005","unstructured":"Bartlett C, Doyal L, Ebrahim S, Ebrahim S, Davey P, Bachmann M, et al. The causes and effects of socio-demographic exclusion from clinical trials. Health Technol Assess. 2005;9:38.","journal-title":"Health Technol Assess."},{"key":"805_CR9","first-page":"1705","volume":"26","author":"P Astern","year":"1999","unstructured":"Astern P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999;26:1705\u201314.","journal-title":"J Rheumatol."},{"key":"805_CR10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.1780380815","volume":"38","author":"CD Radis","year":"1995","unstructured":"Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:1120\u20137.","journal-title":"Arthritis Rheum."},{"key":"805_CR11","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1136\/bmj.2.6203.1461","volume":"2","author":"LJ Kinlen","year":"1979","unstructured":"Kinlen LJ, Sheil AGR, Peto J, Doll R. Collaborative UK-Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ. 1979;2:1461\u20136.","journal-title":"BMJ."},{"key":"805_CR12","first-page":"1","volume-title":"Rheumatology","author":"FE Furst","year":"1998","unstructured":"Furst FE, Clements PJ. Immunosuppressives. In: Klippel JH, Dieppe PA, editors. Rheumatology, vol. Volume 3, Section 9. 2nd ed. London: Mosby; 1998. p. 1\u201310.","edition":"2"},{"key":"805_CR13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/rheumatology\/33.8.735","volume":"33","author":"DPM Symmons","year":"1994","unstructured":"Symmons DPM, Barrett EM, Bankhead CR, Scott DGL, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: Results from the Norfolk Arthritis Register. Rheumatol. 1994;33:735\u20139.","journal-title":"Rheumatol."},{"key":"805_CR14","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/art.20306","volume":"50","author":"M Boers","year":"2004","unstructured":"Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O\u2019Dell J, Pincus T. Making an impact on mortality in rheumatoid arthritis: Targeting cardiovascular comorbidity. Arthritis Rheum. 2004;50:1734\u20139.","journal-title":"Arthritis Rheum."},{"key":"805_CR15","first-page":"696","volume":"34","author":"L Caplan","year":"2007","unstructured":"Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: Prevalence, predictors, correlates, and outcomes. J Rheumatol. 2007;34:696\u2013705.","journal-title":"J Rheumatol."},{"key":"805_CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden Van der","year":"1984","unstructured":"Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u201389.","journal-title":"Arthritis Rheum."},{"key":"805_CR17","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.097774","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68:ii1\u2013ii44.","journal-title":"Ann Rheum Dis"},{"key":"805_CR18","first-page":"1694","volume":"21","author":"TR Jenkinson","year":"1994","unstructured":"Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis: The Bath AS metrology index. J Rheumatol. 1994;21:1694\u20138.","journal-title":"J Rheumatol."},{"key":"805_CR19","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol."},{"key":"805_CR20","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D Heijde Van der","year":"2009","unstructured":"Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811\u20138.","journal-title":"Ann Rheum Dis."},{"key":"805_CR21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/rheumatology\/35.1.66","volume":"35","author":"SD Jones","year":"1996","unstructured":"Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Rheumatol. 1996;35:66\u201371.","journal-title":"Rheumatol."},{"key":"805_CR22","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LC, O\u2019Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281\u20135.","journal-title":"J Rheumatol."},{"key":"805_CR23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"JE Ware","year":"1996","unstructured":"Ware JE, Kosinki M, Keller SD. A 12 item short form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220\u201333.","journal-title":"Med Care."},{"key":"805_CR24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","volume":"62","author":"LC Doward","year":"2003","unstructured":"Doward LC, Spoorenberg A, Cook SA, Whallet D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;62:20\u20136.","journal-title":"Ann Rheum Dis."},{"key":"805_CR25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQoL Group","year":"1990","unstructured":"EuroQoL Group. A new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy."},{"key":"805_CR26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0022-3999(93)90081-P","volume":"37","author":"T Chalder","year":"1993","unstructured":"Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993;37:147\u201353.","journal-title":"J Psychosom Res."},{"key":"805_CR27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0895-4356(88)90138-2","volume":"41","author":"CD Jenkins","year":"1988","unstructured":"Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol. 1988;41:313\u201321.","journal-title":"J Clin Epidemiol."},{"key":"805_CR28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand."},{"key":"805_CR29","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/rheumatology\/kep457","volume":"49","author":"MC Reilly","year":"2010","unstructured":"Reilly MC, Gooch K, Wong RL, Kupper H, Van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatol. 2010;49:812\u20139.","journal-title":"Rheumatol."},{"key":"805_CR30","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3899\/jrheum.100594","volume":"38","author":"F Wolfe","year":"2011","unstructured":"Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, H\u00e4user W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiologic studies: A modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol. 2011;38:1113\u201322.","journal-title":"J Rheumatol."},{"key":"805_CR31","unstructured":"Department of Health. NHS reference costs. https:\/\/www.gov.uk\/government\/collections\/nhs-reference-costs (2014). Accessed 14 September 2015."},{"key":"805_CR32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34:187\u2013220.","journal-title":"J R Stat Soc Series B Stat Methodol."},{"key":"805_CR33","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1136\/ard.2008.098822","volume":"69","author":"A Fouque-Aubert","year":"2010","unstructured":"Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients in ankylosing spondylitis with and without TNF blockers: A systematic review and meta-analysis of randomised placeb-controlled trials. Ann Rheum Dis. 2010;69:1756\u201361.","journal-title":"Ann Rheum Dis."},{"key":"805_CR34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0197-2456(00)00104-5","volume":"21","author":"FY Hsieh","year":"2000","unstructured":"Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2000;21:552\u201360.","journal-title":"Control Clin Trials."},{"issue":"28","key":"805_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11280","volume":"11","author":"C McLeod","year":"2007","unstructured":"McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation. Health Technol Assess. 2007;11(28):1\u2013158.","journal-title":"Health Technol Assess"},{"key":"805_CR36","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/art.38776","volume":"66","author":"A Deodhar","year":"2014","unstructured":"Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration\u2019s comments and concerns. Arthritis Rheumatol. 2014;66:2649\u201356.","journal-title":"Arthritis Rheumatol."},{"key":"805_CR37","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","volume":"74","author":"LK Mercer","year":"2015","unstructured":"Mercer LK, Lunt M, Low AL, Dixon WG, Watson KD, Symmons DP, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015;74:1087\u201393.","journal-title":"Ann Rheum Dis."},{"key":"805_CR38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","volume":"72","author":"JB Galloway","year":"2013","unstructured":"Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72:229\u201334.","journal-title":"Ann Rheum Dis."},{"key":"805_CR39","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/ard.2011.152769","volume":"70","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:1810\u20134.","journal-title":"Ann Rheum Dis."},{"key":"805_CR40","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1136\/ard.2011.153536","volume":"70","author":"R Davies","year":"2011","unstructured":"Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL, et al. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:1831\u20134.","journal-title":"Ann Rheum Dis."},{"key":"805_CR41","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/acr.21663","volume":"64","author":"MM Soliman","year":"2012","unstructured":"Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res. 2012;64:1108\u201315.","journal-title":"Arthritis Care Res."},{"key":"805_CR42","unstructured":"British Society for Rheumatology. British Society for Rheumatology Position Statement on biosimilar medicines (February 2015). http:\/\/www.rheumatology.org.uk\/includes\/documents\/cm_docs\/2015\/b\/bsr_biosimilars_position_statement_feb_2015.pdf (2015). Accessed 6 Oct 2015."}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-015-0805-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T11:20:57Z","timestamp":1718191257000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2474\/16\/347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,11]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1186\/s12891-015-0805-x","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,11]]},"article-number":"347"}}